KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to -$454.5 million.

  • Ionis Pharmaceuticals' Income from Continuing Operations rose 8.45% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$257.0 million, marking a year-over-year increase of 28.53%. This contributed to the annual value of -$454.5 million for FY2024, which is 23.84% down from last year.
  • As of FY2024, Ionis Pharmaceuticals' Income from Continuing Operations stood at -$454.5 million, which was down 23.84% from -$367.0 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$29.4 million for FY2021, and its period low was -$482.4 million during FY2020.
  • Its 3-year average for Income from Continuing Operations is -$363.9 million, with a median of -$367.0 million in 2023.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Income from Continuing Operations surged by 93.90% in 2021, and later slumped by 818.68% in 2022.
  • Ionis Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$482.4 million in 2020, then soared by 93.90% to -$29.4 million in 2021, then crashed by 818.68% to -$270.2 million in 2022, then crashed by 35.82% to -$367.0 million in 2023, then fell by 23.84% to -$454.5 million in 2024.